Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 7/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10306734 | 0.90 | ENPP3 (0.50) | LTA4HESR1ESR2SMN1; SMN2KCNH2 | |
| SCHEMBL1359614 | 0.89 | ESR1 (0.55) | HTTESR1ESR2KCNH2ALDH1A1 | |
| SCHEMBL1358420 | 0.89 | ESR1 (0.54) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL1358193 | 0.89 | ESR1 (0.54) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL1358542 | 0.88 | ENPP3 (0.51) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL10306634 | 0.87 | ESR1 (0.52) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL3115415 | 0.86 | LTA4H (0.52) | HTTLTA4HESR1ESR2NPC1 | |
| SCHEMBL1357972 | 0.82 | HTT (0.56) | HTTLTA4HESR1ESR2NPC1 | |
| SCHEMBL1360621 | 0.80 | HTT (0.53) | HTTLTA4HESR1ESR2NPC1 | |
| SCHEMBL5421491 | 0.79 | HTT (0.52) | HTTLTA4HESR1ESR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| EP-1709021-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | LILLY CO ELI (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1709021-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | GPER1, ESR1, HSD17B11 | HTT 4627/4885LTA4H 811/4885ESR1 2/4885 |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | GPER1, ESR1, HSD17B11 | HTT 4627/4885LTA4H 811/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.